A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease.
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors UCB
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2008 New trial record.